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Background: Strain and estrogens down-regulate Sost/sclerostin and stimulate osteoblastic proliferation.
Results: ER inhibition prevents proliferation. ER inhibition prevents Sost down-regulation by strain or estradiol. Sclerostin
prevents proliferation following strain and not estradiol.
Conclusion: ER promotes proliferation, and ER mediates Sost down-regulation following estradiol ligand stimulation and
ligand independently following strain.
Significance: Selective ER modulators could promote osteogenesis through differential regulation of Sost and proliferation.
Mechanical strain and estrogens both stimulate osteoblast pro-
liferation through estrogen receptor (ER)-mediated effects, and
both down-regulate the Wnt antagonist Sost/sclerostin. Here, we
investigate the differential effects of ER and - in these processes
in mouse long bone-derived osteoblastic cells and human Saos-2
cells.Recruitment to thecell cycle followingstrainor17-estradiol
occurs within 30min, as determined by Ki-67 staining, and is pre-
ventedby theER antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-
5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride.
ER inhibition with 4-[2-phenyl-5,7-bis(trifluoromethyl)pyra-
zolo[1,5-]pyrimidin-3-yl] phenol (PTHPP) increases basal prolif-
eration similarly to strain or estradiol. Both strain and estradiol
down-regulateSost expression, as does in vitro inhibitionor in vivo
deletion of ER. The ER agonists 2,3-bis(4-hydroxyphenyl)-pro-
pionitrile and ERB041 also down-regulated Sost expression in
vitro, whereas the ER agonist 4,4,4-[4-propyl-(1H)-pyrazol-
1,3,5-triyl]tris-phenol or the ER antagonist PTHPPhas no effect.
Tamoxifen, a nongenomic ER agonist, down-regulates Sost
expression in vitroand inbones in vivo. InhibitionofbothERswith
fulvestrant or selective antagonism of ER, but not ER, prevents
Sost down-regulation by strain or estradiol. Sost down-regulation
by strain or ER activation is prevented by MEK/ERK blockade.
Exogenous sclerostin has no effect on estradiol-induced prolifera-
tion but prevents that following strain. Thus, in osteoblastic cells
the acute proliferative effects of both estradiol and strain are ER-
mediated. Basal Sostdown-regulation follows decreased activity of
ER and increased activity of ER. Sost down-regulation by strain
or increased estrogens is mediated by ER, not ER. ER-targeting
therapy may facilitate structurally appropriate bone formation by
enhancing the distinct ligand-independent, strain-related contri-
butions to proliferation of both ER and ER.
Bone architecture is adjusted to be functionally appropriate
for load-bearing through processes in which the strains engen-
dered by loading initiate cascades of responses in resident bone
cells that in turn influence the activity of cells responsible for
bone formation and resorption. The activity of these cells is also
influenced by estrogens. Loss of estrogens following meno-
pause is associated with the development of osteoporosis, a
widespread condition of skeletal inadequacy that has been
hypothesized to reflect a failure of the homeostaticmechanisms
by which bone adapts to its functional load-bearing environ-
ment, commonly referred to as the mechanostat (1). The cellu-
lar mechanisms of the mechanostat are locally influenced by
the estrogen receptors ER7 and ER acting ligand-indepen-
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dently (2–4). This implies that compounds that target the ERs
should be able to enhance the sensitivity of the mechanostat
and so provide effective, mechanically appropriate, treatment
for osteoporosis. The action of the selective estrogen receptor
modulator tamoxifen illustrates this; it reduces fracture risk in
human patients (5), and in mice it synergistically enhances the
effects of loading on bone gain (6).
Loading-induced increases in bone formation involve osteo-
blastic cell proliferation (7, 8) and down-regulation of Sost/
sclerostin (9–11), a glycoprotein secreted primarily by osteo-
cytes. Although a direct effect of sclerostin on strain-induced
osteoblast proliferation has never been shown, sclerostin is
presumed to exert its potent anti-osteogenic effect through
inhibition of the Wnt pathway in neighboring osteoblasts by
antagonizing Wnts binding to their low density lipoprotein
receptor-related (LRP)-5 and -6 co-receptors (12). Neutralizing
antibodies against sclerostin appear to have substantial and sus-
tained osteogenic effects in humans and are now in advanced
stages of clinical trials for the treatment of osteoporosis (13). A
reduction in sclerostin production is also achieved by treatment
with estrogens (14, 15), which also increase osteoblast prolifer-
ation (16). However, the mechanisms by which estrogens and
loading converge to achieve similar outcomes remain largely
unknown.
To investigate the potential mechanisms involved, we have
established amodel in which human female osteoblastic Saos-2
cells are subjected to mechanical strain by four-point bending
of their substrate in vitro (17). These cells have been reported by
ourselves and others to express Sost and sclerostin protein (17,
18). In thismodel, exposure to strain causes down-regulation of
Sost expression over a time course consistent with that
observed following loading of rodent bones in vivo (19, 20),
through mechanisms requiring extracellular signal-regulated
kinase (ERK) signaling (17). ERK is activated in bones subjected
to loading in vivo (21) and in osteoblastic cells subjected to
strain in vitro (22–24). This involves ER and ER acting
ligand-independently (24).
Other effects of strain on ligand-independent ER activity
include activation of genomic estrogen-response elements (25),
ER-mediated nongenomic activation of Wnt/-catenin (26,
27), and AKT (27) signaling. Osteoblastic cells from wild type
(WT) mice proliferate in response to strain in the absence of
estrogenic ligands, whereas similarly derived cells from
ER/mice do not (28, 29). Consistent with this observation,
cells overexpressing ER are more proliferative in response to
strain than cells only expressing endogenous ER (25). The role
of ER in bones’ local adaptive responses to loading has also
been demonstrated in vivo in a number of studies, each ofwhich
show a diminished response to loading in female mice when
ER activity is reduced (2, 30–32).
In contrast, the role of ER in regulating bones’ adaptation to
loading remains controversial. The first in vivo study of ER’s
involvement in loading-related adaptation in bone reported a
lower osteogenic response to axial loading of the ulna in female
ER/ mice compared with WT littermates (32). However,
later studies using knock-outs regarded as being more “com-
plete,” showed enhanced responses to axial loading (2, 33).
ER has been suggested to be the dominant regulator of
estrogen receptor signaling, in part due to its ability to form
heterodimers with ER (34). However, the outcomes of ER
signaling depend on the cellular context in which it operates;
whereas ER largely inhibits transcriptomic changes caused by
estrogen treatment when ER is present, it promotes expres-
sion of a subset of genes when ER is deleted (35). In osteoblas-
tic cells, ER activation increases ER expression (36) and has
been shown to directly bind the ER promoter in other cell
types (37). In contrast, ER can repress ER expression (38),
and mice lacking ER have increased ER in their bones (39).
The outcomes of ER and ER signaling are therefore closely
linked in what has been described as a “ying yang” relationship
determined by a subtle balance between them (35, 40). Com-
pensation for the absence of ER activity by ER, and vice versa,
is demonstrated by the mild effect of loss of either receptor
alone compared with deletion of both ERs in bone and other
tissues (41–43).
Having originally reported the involvement of the ERs in
bones’ adaptive response to loading (30, 32), and more recently
ERK’s involvement in Sost down-regulation by mechanical
strain in vitro (17), we hypothesized that these commonalities
between estrogen and strain signalingmeant that ER and ER
could both contribute to the ligand-independent mechanisms
by which loading down-regulates Sost expression and in turn
regulates proliferation of osteoblasts in response to strain. The
studies reported here used subtype-selective receptor agonists
and antagonists against the ERs to establish the contributions of
ER and ER to the regulation of Sost and proliferation by both
estradiol and strain in osteoblasts.
MATERIALS ANDMETHODS
Reagents and Cell Culture—17-Estradiol (E2) was from
Sigma and dissolved in molecular grade ethanol (EOH). Selec-
tive estrogen receptor modulators used were the ER-selective
agonist 4,4,4-[4-propyl-(1H)-pyrazol-1,3,5-triyl]tris-phenol
(PPT, 0.1 M) (44) or antagonist 1,3-bis(4-hydroxyphenyl)-4-
methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihy-
drochloride (MPP, 0.1 M) (45), the ER agonist 2,3-bis(4-hy-
droxyphenyl)-propionitrile (DPN, 0.1 M) (46) or antago-
nist 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-]py-
rimidin-3-yl] phenol (PTHPP, 0.1M) (47), the context-depen-
dent agonist/antagonist tamoxifen (0.1 M), and the nonselec-
tive ER/ER antagonist fulvestrant (0.1 M, ICI 182780). The
mitogen-activated protein kinase (MAPK)/ERK inhibitor
PD98059 was used at a final concentration of 10 M. All were
fromTocris Bioscience (Bristol, UK). Fulvestrant was dissolved
in EOH, and all other compounds were dissolved in dimethyl
sulfoxide (DMSO). Cells were pretreated with the selective
antagonistsMPP, PTHPP, and PD98059 30min before strain or
E2 treatment, whereas fulvestrant was added 16 h before as
described previously (27).
Wnt3a and recombinant human sclerostin were from R&D
Systems (Abingdon, UK). Sclerostin was dissolved in phos-
phate-buffered saline (PBS) and added 1 h before strain or E2
treatment. The diluents never reached concentrations greater
than 0.1% in the culture medium.
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Cell Culture—All cells were maintained in phenol red-free
DMEM containing 10% heat-inactivated FCS (PAA, Somerset,
UK), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 IU/ml
streptomycin (Invitrogen) (complete medium) in a 37 °C incu-
bator at 5% CO2, 95% humidity as described previously (17).
Saos-2 cells were a kind gift of Dr. S. Allen (Royal Veterinary
College, London, UK). Mouse cortical long bone osteoblastic
cells (cLBObs) were derived from explants of young adult
female C57BL/6 mice as described previously (26, 28, 30). In
brief, cLBObs were explanted by harvesting the diaphyses of
long bones under sterile conditions in PBS containing 1 solu-
tion of antibiotic/antimycotic (PAA, Somerset, UK). All surface
tissues were removed, and marrow contamination was elimi-
nated by repeated flushing with PBS. The bones were subse-
quently chipped into fragments and cultured in complete
medium until cell outgrowth was observed. Like similarly
derived cells from rat bone (48), mouse cLBObs express mark-
ers of osteoblastic differentiation (Runx2, collagen 1 A1, and
osteocalcin) (4) and form mineralized nodules (supplemental
Fig. 1 supplemental Methods), however, they do not express
Sost under the conditions required for in vitro strain experi-
ments (4).
Cell Culture for Proliferation Studies—Cells were seeded at
an initial density of 5000 cells/cm2 (Saos-2) or 10,000 cells/cm2
(cLBObs) on sterile custom-made plastic strips and allowed to
adhere and grow for 24 h. Cells were then serum-depleted over-
night in 2% charcoal/dextran-stripped serum to reduce the
presence of steroids and their basal proliferation, before being
subjected to strain or other treatments the next morning (i.e.
cells were cultured for 2 full days before treatment). Cells were
cultured in the samemedium theywere strained in for the dura-
tion of each experiment.
Cell Culture for Studies of Sost Regulation—Markers of osteo-
blastic differentiation, including Sost, increase in Saos-2 cells
with time in culture (18, 49). Therefore, for studies of Sost reg-
ulation, we used over-confluent cultures that express Sost at a
significantly higher level than subconfluent, proliferative cul-
tures (supplemental Fig. 2). Sclerostin protein is readily detect-
able in confluent Saos-2 cells byWestern blotting, and scleros-
tin levels in the cell culture supernatant are comparable with
previously reported levels in human serum (supplemental Fig.
3).
Using a previously described protocol (17), cells were seeded
at an initial density of 40,000 cells/cm2, allowed to grow for 72 h
before being serum-depleted in 2% charcoal/dextran serum
overnight, and then subjected to strain or other treatment(s) (4
full days in culture before treatment). As was the case for pro-
liferation studies, cells were always cultured in the same
medium they were strained in until they were harvested at the
appropriate time point for quantitative RT-PCR studies.
Straining Cells in Vitro—Strain was applied to the plastic
strips on which cells were adherent using a well established
protocol (17, 26, 27). This involves a brief period (17 min) of
600 cycles of four-point bending engendering a peak strain on
the surface of the strip of 3400 micro-strain (unless otherwise
stated). A testing machine was used (Zwick Testing Machines
Ltd., Leominster, UK) to achieve peak strain rates on and off of
24,000 micro-strain/s, dwell times on and off of 0.7 s, and a
frequency of 0.6 Hz.
Ki-67 Staining toAssess Proliferation—Anti-Ki-67 antibodies
were from Santa Cruz Biotechnology (mouse anti-human,
sc-23900; goat anti-mouse, sc-7846). Ki-67 staining in human
Saos-2 cells was performed essentially as described previously
(50). However, for anti-mouse Ki-67 staining, the antigen was
retrieved by heating in PBS with 0.5% v/v TritonTM X-100
(Sigma), blocked in 1% BSA solution for 30 min, 10% rabbit
serum for 1 h and then 10% horse serum for 1 h at room tem-
perature. In both cases the primary antibodywas used at a 1:100
dilution overnight at 4 °C. NorthernLightTM-conjugated don-
key secondary antibodies were from R&D Systems (Abingdon,
UK) and used at a concentration of 1:100. Slides were mounted
in FluoroshieldTM containing DAPI counter-stain (Sigma) and
imaged on a Leica DMRBmicroscope. All slides in each exper-
iment were imaged under identical conditions.
To assess proliferation by Ki-67 staining, the percentage of
cells stained positive was analyzed under20 magnification in
four randomly chosen fields per slide. In each case, represent-
ative proliferation results are shown as the proportion of all
cells in each field stained positive for Ki-67.
The nuclear distribution of Ki-67 antigen is cell cycle stage-
specific, as documented previously (50–53). Cell cycle stages
were analyzed under 40 magnification using the pattern of
Ki-67 nuclear distribution in individual cells. In each case, the
proportion of actively replicating (Ki-67 positive) cells in G1,
G1/S, S, G2, or M phase are shown. For this, 213  12 Ki-67-
positive nuclei were analyzed in 10 randomly chosen high
power fields per slide. Key results were independently con-
firmed by the author G. L. Galea and L. B. Meakin.
Quantitative RT-PCR—RNeasyTM Plus mini kits (Qiagen,
Sussex,UK)were used to eliminateDNAand extract RNA. First
strand cDNA synthesis was performed using SuperScriptIITM
(Invitrogen). Product copy numbers quantified against stan-
dard curves were normalized relative to 2-microglobulin (2-
MG). PCR primers were designed using Primer3 Plus (54).
Human Sost and 2-MG primers were as described previously
(17). ER primers were also described previously (55). Other
primers were as follows: mouse Sost sense TGCCGCGAGCT-
GCACTACAC and antisense CACCACTTCACGCGCCC-
GAT; mouse 2-MG sense ATGGCTCGCTCGGTGACCCT
and antisense TTCTCCGGTGGGTGCGTGA; mouse OPG
sense TGTGTGTCCCTTGCCCTGACCA and antisense
ACACTCGGTTGTGGGTGCGG; and mouse CCND1 sense
AAGTGGAGACCATCCGCCGC and antisense GCTCC-
TCACAGACCTCCAGCATC.
Quantitative RT-PCR data are presented as pooled results
from two to four independent experiments with n  4–6 in
each experiment. In each case, the control group was set at
100%.
In Vivo Studies—Adult female mice (7 months) were bred
from a previously described ER/ colony (26, 42). Mice were
housed up to five per cage and provided standard mouse chow
andwaterad libitum throughout the study. For RNAextraction
from bone, the surrounding muscle was dissected, the epiphy-
seswere removed, and themarrowwas flushedwith sterile PBS.
Bones were pulverized in QIAzolTM using a TissueLyser LTTM
ER-mediated Regulation of Osteoblast Proliferation and Sost
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(Qiagen, Sussex, UK); RNA was extracted, and genomic DNA
was eliminated using RNeasyTM Plus Universal kits (Qiagen,
Sussex, UK).
To evaluate the effect of tamoxifen (2mg/kg/day), mice were
treated using a regimen that we have previously shown syner-
gistically enhanced loading-related bone gain (6). At 16 weeks
of age (day 1), virgin female C57BL/6 mice were sham-ovariec-
tomized (Sham, n  8) or ovariectomized (n  16). Ten days
after the operation (day 11), the ovariectomizedmice were ran-
domly subdivided into two groups (n  8) and received either
vehicle (peanut oil, 5ml/kg; Sigma) or tamoxifen citrate (Tocris
Cookson Inc., Ellisville, MO) by s.c. injection on days 11, 13, 15,
18, and 21 and were then sacrificed on day 25. All procedures
were in accordance with the Institutional Animal Care and
Home Office, UK, guidelines and approved by the ethics com-
mittee of the University of Bristol or of the Royal Veterinary
College, London, UK.
Statistical Analysis—Statistical analysis was carried out on
SPSS version 17 forWindows. Comparisons of two groupswere
by independent sample t tests, and more than two groups were
compared by analysis of variance with Bonferroni or Games
Howell post hoc adjustments.Data are presented as themean
S.E. p 0.05 was considered significant.
RESULTS
Both Estrogens and Strain Rapidly Stimulate Osteoblastic
Proliferation—Exposure to 1 M E2, or a short period of
mechanical strain, increased the proportion of cLBObs staining
FIGURE 1. Strain and E2 recruit osteoblastic cells to the cell cycle. Primary mouse long bone-derived osteoblasts (A and B) or Saos-2 cells (D and E) were
subjected to strain or treatedwith 1M E2 and fixed 24 h later. C, representative images showing the distribution of Ki-67 antigen in different stages of the cell
cycle as describedpreviously (50–53).A andD,proportionof cells stainingpositive for Ki-67; B and E,distributionof Ki-67-positive cells in different stages of the
cell cycle was determined. Saos-2 cells were treated with 1M E2 before exposure to strain and fixed 8 h later (F). Saos-2 cells were fixed at the indicated time
points following exposure to strain (G) or treatmentwith 1ME2 (I), and thepercentageof cells stainingpositive for Ki-67wasdetermined. Primarymouse long
bone-derived osteoblasts were fixed at the indicated time points following exposure to strain (H). Proportion of Ki-67-positive Saos-2 cells in different stages
of the cell cycle was determined on static vehicle-treated slides or ones harvested 30min following exposure to strain or treatment with E2 using the pattern
of nuclear Ki-67 stain (J). Bars represent means S.E., n 4. *, p 0.05; **, p 0.01; ***, p 0.001 versus static controls.
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positive for the proliferating cell marker Ki-67 24 h later (Fig.
1A). No significant differences were detected between the pro-
portions of Ki-67-positive cells in different stages of the cell
cycle following either treatment (Fig. 1B). A similar prolifera-
tive response to both E2 and strain was observed in Saos-2 cells
(Fig. 1D), with no change observed in the proportion of repli-
cating cells in different stages of the cell cycle 24 h following
treatment (Fig. 1E). This indicates that both estradiol and strain
recruit otherwise Ki-67-negative quiescent cells to the cell
cycle. Pretreatment with E2 for 30 min before exposure to
strain did not significantly change the proportion of cells stain-
ing positive in these asynchronous cultures relative to treat-
mentwith strain or E2 alone (Fig. 1F). Thus, strain and estradiol
similarly recruit a cohort of Ki-67-negative cLBObs or Saos-2
cells to the cell cycle without altering their progression through
it.
Because it is not currently known when osteoblast-like cells
are first stimulated to proliferate following a brief episode of
strain, a time course of proliferation was undertaken. This
showed a significant increase in the proportion of Saos-2 cells
staining positive for Ki-67 within 30 min following strain (Fig.
1G). A similarly rapid response was observed in cLBObs
(Fig. 1H). E2 also initiated Saos-2 proliferation within 30 min
(Fig. 1I). This increase in Ki-67-positive cells was associated
with a transient increase in the proportion of cells in the G1/S
phase of the cell cycle (Fig. 1J). Taken together, these data show
that strain and estradiol both recruit a cohort of osteoblast-like
cells to the cell cycle within 30 min of stimulation.
Strain and E2-induced Proliferation Requires ER—Osteo-
blast proliferation following strain (28) or estradiol treatment
(56, 57) has previously been reported to involve ER. Blockade
of ER with methyl-piperidino-pyrazole (MPP) prevented the
increase in Ki-67-positive cells 8 h following either strain (Fig.
2A) or 1 M E2 (Fig. 2B) and was associated with a significant
reduction in basal proliferation after 24 h (49  4% decrease,
p 0.01 versus vehicle-treated controls). In contrast, blockade
of ER with PTHPP was associated with a significant increase
in basal proliferation with no significant further increase ob-
served following strain or E2 treatment (Fig. 2, C and D). The
increase in basal proliferation following ER blockade was pre-
vented by pretreatment with the ER antagonist (Fig. 2E).
Thus, strain and estradiol involve ER to stimulate prolifera-
tion of osteoblast-like cells, although basal proliferation of
these cells is inhibited by ER.
Proliferation Following Strain and Wnt3a, but not E2, Is
Inhibited by Exogenous Sclerostin—Osteocyte-derived scleros-
tin is presumed to exert its potent anti-osteogenic effect
through inhibition of the Wnt pathway in neighboring osteo-
blasts (12). Consistent with this, pretreatment with 10 ng/ml
recombinant human sclerostin (rhSOST), while not signifi-
cantly changing the proportion of Saos-2 cells stained positive
for Ki-67, prevented the increase in proliferation observed fol-
lowing treatment with 10 ng/ml Wnt3a (Fig. 3A). Similarly,
pretreatment with rhSOST prevented the increase in Ki-67-
positive cells 8 h following strain (Fig. 3B). However, rhSOST
pretreatment did not prevent the increase in Ki-67-positive
cells 8 h following treatment with 1 M E2 (Fig. 3C). Thus,
although both strain and estradiol stimulate rapid proliferation
in osteoblastic cells, they do so by different mechanisms. Only
proliferation caused by strain is prevented by the inhibitor of
Wnt signaling, sclerostin.
Down-regulation of Sost Expression by E2, Activation of ER,
and Inhibition of ER—Both strain and estradiol trigger ER-de-
pendent regulation of transcription in osteoblastic cells (25)
and both down-regulate Sost. E2, at doses equal to or greater
than 10 nM, down-regulated Sost expression within 8 h (Fig.
4A). Selective activation of ER with 0.1 M propyl pyrazole
triol (PPT) had no effect on Sost expression after 8 h (Fig. 4B),
whereas activation of ERwith the agonists diarylpropionitrile
FIGURE 2. Blockade of ER prevents increases in osteoblast-like cell proliferation stimulated by strain and estradiol, whereas blockade of ER
increases basal cell proliferation. Saos-2 cells were subjected to strain (A) or treatment with 1M E2 (B) with or without pretreatment with 0.1M of the ER
inhibitorMPPand fixed8h later. Cellswere subjected to strain (C) or treatedwith1ME2 (D)withorwithoutpretreatmentwith0.1MPTHPPand fixed8h later.
Cells were treated with 0.1 MMPP 30min before treatment with 0.1 M PTHPP and harvested 8 h later (E). Bars represent means S.E., n 4. *, p 0.05; **,
p 0.01 relative to vehicle or static controls.
ER-mediated Regulation of Osteoblast Proliferation and Sost
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(DPN, Fig. 4B) or ERB041 (ERB, supplemental Fig. 4) down-
regulated Sost levels within 8 h.
Because ER activation with PPT has previously been
reported to up-regulate ER expression in osteoblastic cells
(36), we quantified ER expression as a positive control of PPT
action and found it to be elevated at this time point (Fig. 4C).
Conversely, inhibition of ER with 0.1 M MPP significantly
down-regulated ER (Fig. 4D).
ER blockade with MPP also down-regulated Sost expres-
sion 8 h following treatment (Fig. 4E), whereas antagonizing
ER with PTHPP had no effect on basal Sost expression (Fig.
4F). This suggests that, in cells not exposed to strain or estra-
diol, ER ligand-independently maintains Sost expression.
Loss of ER function also resulted in lower Sost levels in
bones from female ER/ mice compared with WT con-
trols (Fig. 4G).
ERNot ERMediates Sost Down-regulation by Strain or E2—
Having established that ER signaling regulates basal Sost
expression, we next investigated whether this is relevant to the
regulation of Sost by strain. As reported previously (17), Sost
expression was down-regulated in Saos-2 cells within 8 h
following exposure to strains equal to or greater than 2000
micro-strain (Fig. 5A). Nonselective blockade of both ER
and ERwith fulvestrant had no effect on basal expression of
Sost, but prevented its down-regulation 8 h following strain
(Fig. 5B) or estradiol (supplemental Fig. 5). Blockade of ER
with the selective antagonistMPP did not prevent significant
Sost down-regulation by strain (Fig. 5C) or E2 (Fig. 5D), irre-
spective of its reduction in basal levels. In contrast, selective
blockade of ER with PTHPP prevented Sost down-regula-
tion following exposure to strain (Fig. 5E) or E2 (Fig. 5F).
ERK Mediates Sost Down-regulation by Strain or E2—Both
ER and ER mediate rapid activation of ERK signaling in
osteoblastic cells subjected to strain (24). In Saos-2 cells ERK
activation is required for Sost down-regulation by strain (17).
Treatment of Saos-2 cells for 24 h with 10M of the ERK inhib-
itor PD98059 did not significantly change cell number or via-
bility (supplemental Fig. 6, a and b), but significantly reduced
ERK phosphorylation (supplemental Fig. 6, c and d). Inhibition
of ERKactivation also prevented Sostdown-regulation by strain
FIGURE 3.Proliferation triggeredby strain orWnt3a, but not by estradiol, is preventedbyexogenous sclerostin. Saos-2 cellswere treatedwith 10 ng/ml
Wnt3a (A), subjected to strain (B), or treated with 1 M E2 (C) with or without 1 h pretreatment with 10 ng/ml or the indicated concentration of recombinant
human sclerostin (rhSOST) and fixed 8 h later. The percentage of cells staining positive for Ki-67was determined. Bars representmeans S.E., n 4. *, p 0.05;
**, p 0.01 relative to vehicle or static controls.
FIGURE 4. Estradiol down-regulates Sost expression, as does activation of ER or inhibition of ER. Saos-2 cells were treatedwith the indicated doses of
E2 and harvested 8 h later (A). Cells were treated with 0.1 M E2, the ER agonist PPT, or the ER agonist DPN and harvested 8 h later, and Sost levels were
quantified (B). Cells were treated with 0.1 M of the ER agonist PPT (C) or the ER antagonist MPP (D) and harvested 8 h later to quantify ER expression. To
evaluate the effect of ER antagonists on Sost levels, cells were treatedwith the ER antagonist MPP (E) or the ER antagonist PTHPP (F) and harvested 8 h later.
Long bones were harvested from ER/ and wild type (WT) mice, and Sost levels were quantified (G). Bars represent themean S.E. *, p 0.05; **, p 0.01;
***, p 0.001 versus the relevant controls.
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(Fig. 6A), E2 (Fig. 6B), and the ER agonist DPN (which has
previously been reported to activate the nongenomic ERKpath-
way (Fig. 6C) (58)).
Tamoxifen used clinically as an ER inhibitor in the treat-
ment of breast cancer, also acts as a nongenomic ER agonist
(59, 60), and in Saos 2 cells it also down-regulated Sost
expression through a mechanism dependent on ERK activa-
tion (Fig. 6D).
Tamoxifen Down-regulates Sost in Vivo—We next sought to
substantiate the in vitro finding that tamoxifen down-regulates
Sost, using an in vivo approach in mice in which we had previ-
ously reported that tamoxifen synergistically enhances bones’
adaptive response to mechanical loading (6). Down-regulation
of Sost by tamoxifen was confirmed in bones in vivo (Fig. 7A)
and was associated with increased expression of cyclin D1
(CCND1, Fig. 7B) and osteoprotegerin (OPG, Fig. 7C), known
Wnt target genes (61, 62).
DISCUSSION
The ability of a bone to withstand loading without fracture
critically depends upon the ongoing (re)modeling within its
constituent tissue. The amount of bone formed as a result of the
various stimuli responsible for (re)modeling is dependent upon
the strength of the stimuli themselves and the responsiveness of
the cells they influence. Twomajor regulators of bone (re)mod-
eling are mechanical strain and estrogens. The experiments
reported here demonstrate that exposure to either estradiol or a
short period of dynamic strain stimulate proliferation, as indi-
cated by an increased proportion of Ki-67-positive cells, in
osteoblast-like cells derived from the weight-bearing cortical
bones of female mice, and in the female human osteoblastic
Saos-2 cell line. Increases in both estradiol and strain initiate
this effect within 30 min, far earlier than we had assumed.
Other early strain-related events in osteoblastic cells include;
increased ligand-independent ER phosphorylation within 5
min (23), ERK activation, alsowithin 5min (23), and an increase
in -catenin translocation to the nucleus within 30 min (26).
One potential pathway by which both strain and estrogen
could exert their effects on osteoblast proliferation, and thus
bone formation, is via theWnt pathway. There are now numer-
ous in vivo studies demonstrating a role for theWnt pathway in
mediating bones’ response to mechanical loading (63–65).
Deletion of the LRP-5 co-receptor reduces the osteogenic
effects of loading (63). Conversely,mice harboringmutations in
LRP-5, which make it insensitive to the antagonistic effects of
sclerostin (66), show enhanced osteogenic responses to
mechanical loading (64, 65). We have previously shown that
Wnt activation in osteoblastic cells subjected to strain is facili-
tated by ER and that activation of -catenin and its transloca-
tion to the nucleus in response to mechanical strain is abro-
gated in osteoblastic cells lacking ER (26, 27).
The finding that exogenous sclerostin prevents proliferation
of osteoblastic cells stimulated by strain suggests that, in the
natural situation, sclerostin down-regulation following me-
chanical loading relieves its inhibition of proliferation stimu-
lated by Wnt proteins present in the local microenvironment.
The parallel finding that exogenous sclerostin has no effect on
estrogen-related proliferation suggests that the pathway from
estrogen to osteoblast proliferation is by a different route in
which Sost down-regulation is either not a rate-limiting step or
is not involved at all. Possible Sost-independentmechanisms by
which estrogens have their effect include ER-mediated effects
on AP-1 transcription (67) or the physical association of ER
with TCF-4 independently of -catenin (68). We have no evi-
dence from this study to suggest a specific role for Sost down-
regulation in the multiple responses of bone cells to estrogens,
except that lower levels of extracellular sclerostin would be
expected to increase the sensitivity to Wnt of any cells sharing
this extracellular environment, given that sclerostin also inhib-
its proliferation following Wnt3a. The observation that down-
regulation of Sost can be associated with different biological
outcomes is not novel; both intermittent and continuous PTH
down-regulate Sost in vivo, however one is anabolic and the
other is catabolic (69, 70).
FIGURE 5. Blockade of ER prevents Sost down-regulation by strain or
estradiol. Saos-2 cells were subjected to the indicated peak strain magni-
tudes and harvested 8 h later (A). Cells were subjected to strain with or with-
out 16 h of pretreatment with 1 M ICI 182,780 (ICI) (fulvestrant) and har-
vested 8 h later (B). Cells were subjected to strain with the indicated
concentrations of MPP (C) or treated with E2 with or without pretreatment
with 0.1 M MPP and harvested 24 h later (D). Cells were subjected to strain
with the indicated concentrations of PTHPP (E) or treated with E2 with or
without pretreatment with 0.1 M PTHPP (F). Sost levels were quantified rel-
ative to2-MG.Bars represent themeanS.E.nsmeansnot significant; *,p
0.05; **, p 0.01 versus the relevant control; #, p 0.05; ##, p 0.01 versus
strained or E2-treated vehicle controls.
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The finding that the increase in proliferation stimulated by
strain and estradiol is mediated by ER, is consistent with a
previous report that nonselective ER blockade with fulvestrant
(ICI 182780) prevents proliferation in rat osteoblasts in
response to the same stimuli (71). In contrast, selective inhibi-
tion of ER increases proliferation, an increase that can be pre-
vented by selectively blocking ER. Thus, ER and ER have
opposite effects on basal osteoblastic cell proliferation, a situa-
tion that is well established in various other cell models
(72–75).
The two ER subtypes also have different effects on Sost/
sclerostin expression. Sclerostin is naturally produced primar-
ily by osteocytes, and ideally, we would have wished to investi-
gate its regulation in primary osteocyte cultures, but obtaining
cultures of sufficient purity for large scale in vitro loading
experiments is not currently possible. Unfortunately, the well
established MLO-Y4 and MLO-Y5 osteocyte-like cell lines
have been found to express very low to undetectable levels of
Sost (76, 77). The recently reported IDG-SW3 cell line that
replicates osteoblast to osteocyte differentiation does synthe-
size Sost, however, this requires at least 14 days of treatment
with osteogenic differentiation medium that promotes miner-
alization (77) and mineralized cultures cannot be used for
experiments involving strain. We therefore used the human
osteoblastic Saos-2 cell line for our experiments because these
cells secrete sclerostin when highly confluent (16, 17), and in
this model exposure to strain causes down-regulation of Sost
expression over a time course consistent with that observed in
vivo (18).
In cultures of these cells, both estradiol and strain down-
regulate Sost/sclerostin expression through either ER and/or
ER as evidenced by its blockade with fulvestrant. However,
whereas the ER agonist PPT has no effect on basal Sost levels,
the ER antagonist MPP causes down-regulation. Thus,
although increased ER activity does not increase basal levels of
Sost, decreased ER activity causes Sost down-regulation. Con-
sistent with this, loss of ER also results in lower Sost levels in
bones from female ER/mice compared with WT controls.
FIGURE 6.MEK/ERK blockade prevents ER-mediated Sost down-regulation. Saos-2 cells were subjected to strain (A) or treated with 0.1 M E2 (B), DPN (C), or
Tamoxifen(Tam) (D)withorwithout30minofpretreatmentwith10MPD98059andharvested24hlater.Sost levelswerequantifiedrelativeto2-MG.Bars represent
themean S.E., n 12. **, p 0.01; ***, p 0.001 versus vehicle control; ##, p 0.01; ###, p 0.001 versus the strained or agonist-treated vehicle group.
FIGURE 7.Down-regulation of Sost expression by tamoxifen occurs in vivo as well as in vitro. Adult female mice were ovariectomized (OVX) and treated
with tamoxifen. Sost (A), cyclin D1 (CCND1) (B), and osteoprotegerin (OPG) (C) levels were quantified relative to 2-MG. Bars represent the mean S.E. *, p
0.05; ***, p 0.001 versus Sham and ovariectomized-vehicle in each case.
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In contrast, the ER agonist DPN and the partial ER agonist
tamoxifen both cause down-regulation of Sost, whereas the
ER antagonist PTHPP has no effect. This shows that although
increased ER activity down-regulates basal Sost, the decreased
ER activity does not increase it. Selective antagonism of ER
rather than ER also prevents the down-regulation of Sost by
acute increases in either estradiol or strain.
The differences we report on the effects of ER and ER on
Sost expression were unexpected; we had anticipated that ER
would mediate strain-related down-regulation of Sost because
the absence of ER in female (but not male) mice has been
repeatedly associated with a lower adaptive response to applied
loading than in their WT background (30–32). This has been
assumed to be the result of ER’s ligand-independent involve-
ment in a number of the early stages of bones’ osteogenic/anti-
resorptive response to loading. ER’s strain-related functions
include its association with ERK in the signalosome (24), with
the IGF receptor’s response to IGF (27), and its role in the trans-
location of -catenin from cytoplasm to nucleus (26). Instead,
these findings notwithstanding, our present data suggest that,
in human female osteoblastic cells at least, the effects of acute
changes in strain or estradiol are mediated primarily by ER.
This inference is based on a number of elements in our present
study as follows. (i) Selective activation of ER imitates the
ERK-mediated down-regulation of Sost by strain or estradiol.
(ii) Tamoxifen, which acts as a nongenomic ER agonist while,
at least in other cell types, antagonizing ER (59, 60), also imi-
tates Sost down-regulation by strain or estradiol. (iii) Preven-
tion of Sost down-regulation by nonselective inhibition of ERs
with fulvestrant is not achieved by selective blockade of ER,
whereas blockade of ER prevents Sost down-regulation by
both strain or estradiol.
The finding that MAPK/ERK blockade prevents ER-medi-
ated Sost down-regulation is consistent with the report that
ER, like ER, is involved in the rapid strain-related activation
of ERK signaling in osteoblastic cells (24). The potential
involvement of ERK signaling suggests a nongenomic mode of
action of ER, at least in the context of strain, although the
involvement of this signaling pathway in awide range of cellular
processes limits interpretation of this result. Nongenomic acti-
vation of ERK signaling by either ER or ER in a variety of cell
types is increasingly being associated with diverse biological
outcomes (78, 79). That ER activation may regulate Sost
expression and activate ERK signaling has recently been sug-
gested by the report that feeding rats soy isoflavones, which act
as potent and relatively selective ER agonists (80, 81),
increases ERK phosphorylation in bone and down-regulates
Sost/sclerostin levels similarly to E2 treatment in vivo (15). The
potential use of soy isoflavones for the treatment of osteoporo-
sis is currently being investigated (82). We also demonstrate
that tamoxifen reduces Sost expression in vivo, a finding con-
sistent with an effect through ER. The potential for ER to
mediate the therapeutic effects of tamoxifen treatment has
been proposed elsewhere in the context of breast cancer (60),
and tamoxifen administration has a profound osteogenic effect
in cancellous regions of mouse bones, where ER is intensely
expressed in osteocytes (83). A role for ER inmediating bone’s
response to loading is consistent with tamoxifen synergistically
enhancing bone gain in the tibiae of female mice subjected to
mechanical loading (6). In this regard, the effects of tamoxifen
are similar to those of parathyroid hormone and EP4 targeting
compounds, both of which have been reported to down-regu-
late Sost (17, 76) and synergistically enhance bone gain follow-
ing loading (84–86).
The inference that Sost regulation by strain is mediated by
ER is also consistent with the original report by Lee et al. (32)
that mice with incomplete ablation of ER activity show an
impaired increase in cortical bone formation following loading
of the ulna. However, subsequent reports in mice with more
complete ER ablation (32) have showna greater cortical osteo-
genic response to loading (2, 33). It is only possible to speculate
on the inconsistencies between these studies because of poten-
tially compensatory up-regulation of ER (39) and opposite
global transcriptomic influences of ER with or without ER
(35). What is clear is that the role of ER in the bone’s adapta-
tion to loading remains controversial and, compared with ER,
under-studied. It is also becoming increasingly apparent that
the functions of ER and ER in determining the osteoregula-
tory effects of loading are dependent not only on the systemic
biochemical/hormonal systemic context but also on the region
of the bone involved (2).
Although this study investigates the role of the ERs in differ-
entiated osteoblasts, ERs also play an active role during osteo-
blast lineage progression. Both ER and ER are expressed in
stromal pre-osteoblasts (83, 87, 88), which either proliferate to
maintain the progenitor pool or differentiate into osteoblasts
(as schematically represented in Fig. 8).Mechanical loading and
E2 both increase osteoblast differentiation (89–91), and the
mechanismbywhich strain promotes osteoblast differentiation
involves LRP-independent activation of -catenin (89, 92, 93).
However, the role of the ERs in these processes is not clearly
understood. Both ERs may mediate osteoblast differentiation
following E2 treatment (94), although ER inhibits mineraliza-
tion (95) and bone morphogenetic protein-induced differenti-
ation (96). Marrow stromal cells from individuals with a hypo-
morphic ER have lower estradiol responsiveness but
enhanced intrinsic differentiation (97). ER also inhibits the
transcriptional activity of themaster regulator of the osteoblast
lineage, Runx2 (98).
Loading and estrogen both promote proliferation of pre-os-
teoblasts (99–102), more differentiated osteoblastic cells (as
used in the present study), and bone-lining cells (7, 8, 16). The
proliferative effects of strain on osteoblastic cells have repeat-
edly been found to require ligand-independent activation of
ER (28, 29, 71). Similarly, estrogen promotes proliferation
through a nongenomic function of ER (56). In this study, ER
promotes proliferation following strain or estradiol treatment,
whereas ER suppresses basal proliferation. Intriguingly, in
MG63 cells, estrogen acting through ER has also been
reported to suppress proliferation (103).
In mature osteoblasts in vivo, the osteogenic effects of estra-
diol requires a fully functional ER (104), whereas the osteo-
genic effects of loading do not require the ligand-binding AF2
domain of this receptor (4). Ligand-independent functions of
ER activated in osteoblastic cells by strain include its potenti-
ation of the IGF receptor (27) and the translocation of
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-catenin to the nucleus (26). Although roles for ER in the
responses of these cells to strain are largely unknown, inMG63
cells ER is required for estradiol to up-regulate expression of
matrix components (103). ER also selectively regulates the
expression of genes related to migration (105), a process that is
likely to be involved in matrix secretion.
Following secretion ofmatrix, osteoblasts become quiescent,
terminally differentiate into osteocytes, or become apoptotic.
Loading and estrogen both reduce apoptosis (24, 106–109),
and estradiol has been shown to contribute to anti-apoptotic
processes by activation of either ER or ER through non-
genomic mechanisms in a variety of cell models (55, 107, 110).
In osteocytic MLO-Y4 cells, mechanical strain exerts anti-apo-
ptotic effects throughERKactivation that requires nongenomic
signaling through both ERs (24). Apoptosis, especially of osteo-
cytes, promotes osteoclast recruitment (108, 111), and ER
expression in osteoclasts is required for maintaining trabecular
bone mass in female mice (113). ER also suppresses the
expression of osteoclastogenic cytokines in osteoblastic cells
(117–119).
Together, these data suggest that ER plays key roles early on
in the osteoblast lineage through its enhancement of prolifera-
tion, which is consistent with the recent finding that in mice
selective deletion of ER in pre-osteoblast mesenchymal cells
using Prx-cre or Osterix1-cre is associated with reduced corti-
cal thickness due to reduced bone formation. In contrast, its
deletion later in the lineage using Col1a1-cre has no such effect
(112). Conversely, as has previously been suggested byCao et al.
(103), the functions of ERmay relate to the formation of post-
proliferative matrix-secreting cells.
Although it is difficult to reconcile in vitro datawith those from
studies in mice in vivo, the additional step of relating the data to
human patients is even more problematic. However, with age
there is a reduction in circulating estrogens in both men and
women that is accompanied by an increase in serum sclerostin
(113). Reduced Wnt signaling due to elevated sclerostin levels,
impairing the proliferative context in which loading acts, could
partially explain the reducedabilityofbone toadapt to itsmechan-
ical loading environment post-menopausally and in later life. Any
attempt to explain this in termsof the activity of eitherERorER
would at this stage be speculation.
In conclusion, ER and ER differentially regulate the
responses of osteoblastic cells to acute changes in their ligand
(estrogens) and to mechanical strain, thus influencing the con-
text in which these proliferative stimuli act (schematically rep-
resented in Fig. 8). Exposure of osteoblastic cells in vitro to
either a short period of mechanical strain or to an acute
increase in the estradiol concentration in their environment
stimulates proliferation mediated at least in part through ER.
Such exposure to changes in estradiol concentration and to
short exposure to dynamic strain also down-regulates the
expression of theWnt antagonist Sost/sclerostin.Whereas ER
maintains basal expression of Sost, ER activity inhibits basal
proliferation. However, it is ER and not ER that mediates
acute reduction in Sost in response to either changes in estro-
gens or strain. The (re)modeling response of bones to either
strain or estrogens involves control of targeted formation and
resorption. The extent of this osteogenic/anti-resorptive
response will depend inter alia upon both the “proliferative
context” in which it operates and the strength/duration of the
stimulus to which the responsive cells are subjected. The data
presented here suggest that the contribution of ER is primarily
to the proliferative context, although the contribution of ER is
to the acute response of the resident bone cells to theirmechan-
ical and hormonal environment. In the case of exposure to
FIGURE 8.Schematic illustrating the roles of ER andER at different stages of theosteoblastic lineage. Early osteoblasts canproliferate or differentiate,
and although ER promotes their proliferation (28, 56, 114) and suppresses differentiation (94–96), there is evidence that ER promotes differentiation (94,
103) while inhibiting proliferation (103). In more mature osteoblasts, ER promotes proliferation and ER inhibits it, as we have shown in this study. ER and
ER both contribute to matrix production (103, 115, 116), and ER also selectively regulates genes associated with cell migration (105). In osteoblastic cells
exposed to mechanical strain, ER facilitates other osteogenic signaling pathways, specifically IGF (27) and Wnt/-catenin signaling (26). ER and ER also
contribute to anti-apoptotic signaling (55, 107, 110), and in osteocyte-like cells subjected to strain this involves ERK activation (24). Both ERsmay also influence
osteoclastogenic cytokine expressionby osteoblastic cells (55, 95, 117–119). Both receptors regulate Sost expression, as describedhere; ERmediates its acute
down-regulation by strain and estradiol, and ER maintains its basal expression. However, understanding the physiological context in which this complex
interaction operates requires further investigation. -cat, -catenin.
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strain, this response involves reduced expression of the Wnt
antagonist Sost.
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